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In general, radio- or chemotherapy does not discriminate between
normal and malignant cells and, for optimal anti-tumour effect,
toxic effects on normal tissues often have to be accepted. For the
majority of agents, myelosuppression is dose-limiting but all
agents can produce significant non-haematologic effects which
may limit individual doses (e.g. haemorrhagic cystitis for
oxazophosphorine-based alkylating agents; neurotoxicity for
taxoids; vomiting for cisplatin) and/or cumulative doses (e.g.
neurotoxicity and nephrotoxicity for cisplatin; cardiac toxicity for
anthracyclines). Fortunately, acute nausea and vomiting are better
managed now than they were a decade ago, with the wide avail-
ability of 5-HT3 receptor antagonists, but other non-haematologic
toxicities remain important problems. These toxicities are most
pronounced when higher doses or longer term treatment is
planned, but they can also occur when standard dose therapy is
given, causing significant patient symptomatology and limiting
the delivery of ‘curative intent’ treatment.
In general, several approaches are available which may prevent
the development of serious toxicities, without necessarily sacri-
ficing anti-tumour efficacy. These include: (1) changing the
schedule of drug administration (e.g. infusion rather than bolus
anthracyclines); (2) changing the route of drug administration (e.g.
intraperitoneal cisplatin instead of intravenously (i.v.)); (3)
biochemical modulation of the drug (e.g. administration of leucov-
orin ‘rescue’ with methotrexate); (4) addition of chemoprotectors
(e.g. glutathione (GSH) or WR-2721 for cisplatin; dexrazoxane for
anthracyclines; mesna for ifosfamide).
An ideal chemoprotective agent is an agent without side-effects,
chemoprotective capacities and which does not reduce anti-tumour
efficacy. Reducing the morbidity and mortality of our present anti-
neoplastic regimens with the concomitant use of chemoprotective
agents may make anti-tumour treatment more tolerable for patients
and may permit for dose-escalation of radio- and chemotherapy,
which could lead to improved survival.
WR-2721 (amifostine; Ethyol) and GSH are chemoprotective
agents. WR-2721 is a synthetic aminothiophosphorate. GSH is an
endogenous intracellular tripeptide thiol-containing compound.
An important consideration in the study of chemoprotectors is the
relative selectivity of the protective action, because these agents,
theoretically, might also inhibit cytotoxic and anti-tumour activity.
In vitro and in vivo experiments with WR-2721 did not show inhi-
bition of anti-tumour activity (Yuhas, 1980; Calabro-Jones et al,
1988; Smoluk et al, 1988; Kemp et al, 1996). In fact, several in
vitro and animal studies were able to demonstrate an increased
cytotoxicity when tumours were exposed to chemotherapy
combined with WR-2721 (Valeriote and Tolen, 1982; Millar et al,
1982; Treskes et al, 1994; Douay et al, 1995; Taylor et al, 1997).
Intracellular GSH correlates in vitro and in vivo with an increase
in resistance to chemotherapeutic drugs, but extracellular GSH
(i.e. exogenous) does not reduce cytotoxic activity (Zunino et al,
1989; Leone et al, 1992; Hamers et al, 1993). In contrast to the
locally active chemoprotective agent mesna (sodium 2-mer-
captoethane sulphonate), which protects the bladder against
cyclophosphamide-induced cystitis, GSH and WR-2721 are
expected to protect more organs against chemo- and radiation
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cytoprotection of kidney, heart, lung, liver, mucosa and bone
marrow is predicted (Utley et al, 1976; Washburn et al, 1976).
Based on the level of the enzyme, g-glutamyl transpeptidase,
necessary for the membrane transport of GSH and radiolabelled
GSH, GSH is likely to have protective effects on kidney, liver and
peripheral neurons (Romero et al, 1990; Hamers et al, 1993; Ercan
et al, 1994).
In addition, the potential role of these agents in preventing
mucosal, cardiac, oto- and neurotoxicity and in preventing the
development of secondary malignancies in patients treated with
radio- or chemotherapy will be discussed. Special attention will be
paid to the characteristics, mechanisms of action, indication for
use and the future prospects of these drugs.
WR-2721 CHARACTERISTICS
WR-2721 (amifostine, (S-2-(3-aminopropylamino)-ethylphos-
phorothioic acid, Ethyol) was developed by the United States
Army at the Walter Reed Army Institute of Research in the late
1950s, as part of the Anti-Radiation Drug Development Program
to protect soldiers on the battlefield. This agent was selected from
4000 sulfhydryl compounds screened for further clinical evalua-
tion because it was found to be one of the least toxic and most
effective. Although it produced only slight effects in cultured cells
as a single agent, the addition of alkaline phosphatase markedly
increased the protective effects (Calabro-Jones et al, 1985; Mori et
al, 1984). This was because WR-2721 is, in fact, a pro-drug which
must be dephosphorylated to the active metabolite WR-1065
(Figure 1). The ability of WR-2721 to selectively protect normal
tissues against both radiation and chemotherapeutic drugs is
accounted for, in part, by higher uptake in normal as compared to
tumour tissue (Calabro-Jones et al, 1985). This differential uptake
is probably caused by differences in the microenvironment of
alkaline phosphatase in normal and malignant tissue. High
concentrations of this enzyme are found in capillaries and arteri-
oles. In contrast, lower levels of alkaline phosphatase in capillaries
of malignant tissue are common (Calabro-Jones et al, 1988). In
addition, uptake of WR-1065 is highly dependent on pH. Because
of their predominantly anaerobic metabolism, tumour tissues tend
to have a lower pH than normal tissue. The decreased pH results
in significantly reduced uptake of WR-1065 by tumour cells
(Calabro-Jones et al, 1988). Also a difference in carrier-mediated
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Table 1 Comparative clinical studies with WR-2721
Reference Study Tumour No. of Schedule of protectant Antineoplastic regimen
design type patients
Betticher et p,r NSLC W 11 910 or 683 mg m22 over 15 min prior and for CBDCA 600 mg m22 every 4 weeks for 4 cycles
al (1995) C 10 2 doses after CBDCA
Budd p,r NSCL W 17 910 mg m22 over 15 min before and 2 hours CBDCA 500 mg m22 every 4 weeks
et al (1996) C 20 after CBDCA
Kemp p,r Ovar. W 122 910 mg m22 over 15 min prior to CYC CYC 1000 mg m22 then CDDP 100 mg m22 every
et al (1996) C 120 3 weeks for 6 cycles
Glick co Dif. T 40 450–1100 mg m22 as a 15–20 mg m22 min21 CYC 1200–1800 mg m22
et al (1984) infusion over 15 min prior to CYC
Glover co Ovar. T 21 740 mg m22 over 15 min initiated 30 min CYC 1500 mg m22
et al (1986) prior to CYC
Mollman p Dif. W 28 740 mg m22 in those receiving CDDP  CDDP 20–120 mg m22 and other various agents
et al (1988) C 41 120 mg m22 monthly
Poplin p,r Rect. W 48 910 mg m22 administered M 20 mg m22 every 6 weeks
et al (1994) C 49 15 min prior to M
Wooley co Ovar. T 10 250–1000 mg m22 30 min before or divided CYC 1000–1352 mg m22
et al (1983) dose 30 min before and 6 h after CYC
Planting p,r Head/Neck W 36 740 mg m22 over 15 min prior to CDDP CDDP 70 mg m22 4 week21 for 6 weeks
et al (1996) C 38
Liu et p,r Rect. W 50 340 mg m22 over 15 min prior to every 2.25 Gy Whole pelvis irrad. with 2.25 Gy 4 days/week 
al (1992) C 50 for 5 weeks to a total of 45 Gy then 1 or 2
conedown of 7.20 Gy over 4 days
Brizel et p,r Head/Neck T 315 200 mg m22 30 min before radiation 1.8–2.0 Gy per day to total of 60–70 Gy
al (1998)
Buntzel p,r Head/Neck W 25 500 mg prior to CBDCA CBDCA 70 mg m22 day 1–5 and 21–25
et al (1998) C 14 Irrad. 2 Gy 5 days per week to a total of 60 Gytransport in tissues may play a role as seen for GSH (Hamers et al,
1993; Grdina et al, 1995). A difference not only in vascular supply
but also in adhesion molecules and transport molecules in vessels
might be an explanation for the preferential protection of tumour
tissue (Nooijen et al, 1998).
In vitro and in vivo studies in animals have shown that WR-
2721 provides selective protection of normal tissue against the
toxicity of radiation and numerous chemotherapeutic agents,
including alkylating agents, cisplatin, docetaxel and 5-fluorouracil
(5-FU). In animal studies an increasing dose of WR-2721 resulted
in better radioprotection. When given with cisplatin, the timing of
WR-2721 administration might be important, because WR-2721
can form a complex with this drug very rapidly (Thompson et al,
1995). However, because 90% of the WR-2721 is cleared from the
plasma within 6 min after administration of 740 mg m22 WR-2721
over 15 min, injection of cisplatin 15 min after WR-2721 adminis-
tration can be carried out with no WR-2721 or metabolite detected.
This permits both drugs to be given without complex formation
(Shaw et al, 1986; Korst et al, 1997). When, however, 910 mg m22
WR-2721 is given there is evidence of saturable metabolism
(Shaw et al, 1994). Fifteen minutes after the administration of
WR-2721 there is still approximately 15% WR-2721 left in the
plasma (range 1–30%, mean 20%). This remnant can form
complexes with cisplatin. In carboplatin and paclitaxel in vitro and
in vivo no adverse effect on tumour response is found when WR-
2721 is given simultaneously (Taylor et al, 1997; Budd et al,
1996). Based on these results, WR-2721 drug complex formation
might be not so important for these two drugs.
WR-2721 is unable to pass through the blood–brain barrier and
cannot be used as a protective agent for the brain and spinal cord
(Washburn et al, 1976; Millar et al, 1982). The drug-related toxici-
ties in humans (Kemp et al, 1996) include hypotension (57%),
flushing (39%), sneezing (25%), dizziness (11%) and chills (4%).
Based on the side-effects, pharmacokinetic interactions and
chemotherapeutic or radiotherapeutic schedule used, different
concentrations and schedules of WR-2721 are applied. In some
regimens, carboplatin is combined with three doses of amifostine
because of the high concentration of the active carboplatin species
during the first 4 h after administration. In general, for a short and
frequent schedule (as radiotherapy), lower WR-2721 concentra-
tions are used. The dose-limiting toxicity is hypotension. In the
clinical setting, 200 mg m22 to 910 mg m22 WR-2721 adminis-
tered in a 15-min infusion, is a tolerable dose when it is combined
with anti-emetics and dexamethasone in the higher WR-2721
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Anti-tumour effect Haematological protection (W vs C) Non-haematological protection (W vs C) Conclusion
Resp. 50% vs 22% (NS) NS No significant protection
Med. Surv. 14 vs 9 month (NS)
Resp. NS Incidence of granulocytopenia Protection against haematological
12 vs 20% toxicity
Median nadir platelet count
increased 72%
Path. Resp. 43% vs 36% Incidence of grade 4 neutropenia Patients who discontinued therapy Protection against haematological
Med Surv. 31 vs 31 month and fever: 10 vs 27% because of nephrotoxicity: 0 vs 8% and non-haematological
Neurotoxicity and ototoxicity not toxicity
significantly different
Granulocyte nodirs increased 67–88% Protection against the CYC
induced haematological toxicity
Mean nadir WBC count increased Protection against CYC induced
42% haematological toxicity
Mean nadir granulocyte count
increased 130%
Incidence of neuropathy reduced: 25% Reduced CDDP induced
vs 47–100% neuropathy
Med Surv. 7.2 vs 6.3 months (NS) WBC and platelet nadirs not Data were not controlled No significant protection
significantly different
WBC and platelet nadirs not No significant protection
significantly different between
treatments
Resp. 70% vs 57% Platelet toxicity 3/4: 3% vs 17% Ototoxicity 22% vs 34% Protection against
Treatment delay based on bone haematological toxicity
marrow toxicity 6% vs 21%
Resp. 16% vs 10% (NS) Significant difference in late severe Protection against the late
toxicity severe toxicity
Resp. 80% vs 78% (NS) Grade 2 xerostomia 50% vs 76% Protection against the acute
onset grade 2 xerostomia 50 Gy vs 42 Gy severe toxicity
Resp. 79% vs 64% Platelet toxicity 3/4: 0% vs 29% Grade 3/4 mucositis 0% vs 86% grade Protection against the acute
2 late xerostomia 17% vs 55% and late toxicityconcentrations. Premedication with 20 mg dexamethasone intra-
venously and a serotonin receptor antagonist modifies these
effects so that only 1% of infusions are associated with WHO
grade 3/4 vomiting and less than 1% of patients require infusion
interruption for hypotension (Planting et al, 1996). No dexametha-
sone premedication is necessary at a dose of 200 mg m22 amifos-
tine, as used in radiotherapy applications. This drug is registered in
many countries for the prevention of cisplatin-induced nephrotox-
icity. Beside the indications as a chemoprotective agent, WR-2721
is investigated as a bone marrow stimulant in patients with
myelodysplastic syndrome. At a dose of 200 mg m22 three times a
week, haematological activity is shown (List et al, 1997). The US
Federal Drug Agency (FDA) recommended dose for chemoprotec-
tion in adults is 910 mg m22 administered as a 15-min infusion 30
min before the start of the chemotherapy. The price of 500 mg
WR-2721 in the Netherlands is approximately US $250. Per
chemotherapy course this would mean an additional expense of
approximately US $650.
GSH CHARACTERISTICS
GSH is a naturally occurring tripeptide (g-glutamine–cysteine–
glycine) and the most abundant intracellular thiol (Figure 2).
Although all tissues produce GSH, some synthesize more than
others. The liver, for instance, is a net exporter of this peptide.
Exogenously administered GSH is reported to increase intracel-
lular GSH levels, but this increase is not caused by the uptake of
exogenously administered GSH (Meister, 1983). This intracellular
uptake of GSH from plasma almost always involves its degrada-
tion by membrane-bound g-glutamyl transpeptidase, followed by
transport into the cell of the individual amino acids and resynthesis
of GSH by g-glutamylcysteine synthetase and glutathione
synthetase. Glutamate is coupled by g-glutamyl transferase to
another amino acid, and this dipeptide is transported across the cell
membrane (Figure 3). Glutathione synthetase is not inhibited by
glutathione, therefore higher intracellular GSH concentrations can
be reached (Meister et al, 1983). Organs such as kidney, liver and
peripheral nerves containing high levels of transpeptidase activity
are important scavengers of plasma GSH. The kidney is the most
important scavenger, but peripheral nerves also contain quite high
levels of g-glutamyl transpeptidase, indicating they are also
capable of importing exogenous GSH. The selective protection of
GSH for normal compared to tumour cells is likely related to low
membrane  g-glutamyl transpeptidase activity in tumour cells
(Hamers et al, 1993). The organs listed containing a high level of
g-glutamyl transpeptidase activity are those which theoretically
could be protected by exogenous GSH administration following
radiation or chemotherapy. The half-life of GSH is approximately
15 min after 2000 mg m22 GSH. In 90 min following infusion, the
urinary excretion of GSH and cysteine was increased 300-fold and
tenfold respectively (Aebi et al, 1991). Compared with a lower
dose, the disposition of GSH appears to be dose-dependent and
subject to saturation kinetics. Theoretically, the timing of the start
632 GAP Hospers et al
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Figure 1 WR-2721 is converted to the active dephosphorylated metabolite
(WR-1065) by the enzyme alkaline phosphatase (AF)
NH2(CH2)3-NH(CH2)2-S-PO3H2         NH2(CH2)3-NH(CH2)2-SH
WR-2721 AF WR-1065of the GSH infusion before the cisplatin might be critical because,
like WR-2721, GSH can form a complex with cisplatin. When
cisplatin is given 30–60 min after the GSH infusion in a ratio of
GSH:CDDP of 30:1 there is protection without interfering with
therapeutic activity (Zunino et al, 1989). In order to maximize the
cytoprotective effect of GSH, short cisplatin infusions should be
given. In the clinical setting 1500–3000 mg m22 GSH is adminis-
tered i.v. approximately 15 min before chemotherapy (Parnis et al,
1995; Smyth et al, 1997; Bogliun et al, 1996). In contrast with
WR-2721, GSH itself produces no toxicity. This drug is not regis-
tered as a chemoprotective agent. In the USA, GSH is also being
studied in patients with HIV infection to assess the potential
benefit of increasing the abnormally low blood GSH levels found
in this setting. In addition, the cytoprotective potential of this drug
is being studied with both chemotherapy and radiotherapy in
several clinical studies (Di Re et al, 1990, 1993; Hamers et al,
1993; Locatelli et al, 1993).
MECHANISMS OF PROTECTIVE ACTION OF
WR-1065 AND GSH
WR-1065 and GSH act as naturally occurring thiols. They prevent
cell damage by scavenging of hydroxyl radicals, the chemical
repair of DNA radicals by hydrogen atom transfer, the depletion of
oxygen as a consequence of thiol oxidation, the protection of key
sulfhydryl enzymes through formation of protein–aminothiol
mixed disulphides, and the facilitation of DNA repair through
binding of the disulphide to DNA resulting in stabilization of DNA
and inhibition of replication. WR-2721 has a similarity in structure
to polyamines and, also like polyamines, has a high affinity for
DNA and polyamine effects on processes related to DNA structure
and synthesis (Murley and Grdina, 1995; Murley et al, 1997;
Weiss, 1997). WR-1065 can give, in concentrations from 4 mM in
Chinese hamster ovary cells, a delay in the cell cycle and an inhi-
bition of topoisomerase IIa activity (Murley et al, 1997). Based on
the above described mechanisms, WR-1065 and GSH act as cyto-
protective agents following radiation and with chemotherapeutic
drugs such as alkylating agents, cisplatin and doxorubicin. The
mechanisms for protection of radiation effects by these drugs
occur probably by scavenging free radicals, reaction with alkyl
groups, prevention of platinum-adduct formation and a faster
DNA repair (Treskes et al, 1991). Preclinical and clinical studies
have shown that WR-2721 also provides selective protection of
normal tissue against the toxicity of paclitaxel, docetaxel and 5-FU
(Wasserman et al, 1981). In a non-randomized trial, it appeared
that amifostine pretreatment has the tendency to reduce the
paclitaxel-induced arthralgia, myalgia, myelosuppression and
neuropathy (DiPaola et al, 1998). The mechanism(s) by which it
(they) protects against paclitaxel, docetaxel and 5-FU toxicity is
not known, or even if they protect in the clinic. In addition, confir-
matory randomized data are required before it can be stated that
amifostine provides protection for the effects of these agents in the
clinic. It may be that a faster DNA repair is responsible for the
protective activity of 5-FU.
CLINICAL RESULTS OF RADIO- AND
CHEMOTHERAPY PROTECTION BY WR-2721
In Table 1, different comparative clinical trials using WR-2721 as
radio- and chemoprotective agent are presented; unfortunately,
most studies are small. Most comparative trials showed WR-2721
to reduce the severity and/or incidence of granulocytopenia and
thrombocytopenia observed after cisplatin (CDDP) plus cyclo-
phosphamide or cyclophosphamide alone compared with a control
group or in patients who crossed to chemotherapy alone. The
largest randomized trial is that of Kemp et al (1996). In total, 242
patients with advanced epithelial ovarian cancer were randomized
to treatment with cyclophosphamide (1000 mg m22) plus CDDP
(100 mg m22) with or without amifostine (910 mg m22), every 3
weeks for 6 cycles. WR-2721 was shown to reduce the renal toxi-
city from cisplatin given in a dose of 100 mg m22 CDDP. The
survival in the two groups was similar, providing reassurance that
WR-2721 did not cause tumour protection. As a result of the
reduction in renal, haematologic and neurotoxicity only 9% of
patients in the WR-2721 arm discontinued chemotherapy,
compared with 24% in the control arm.
Liu et al (1992) published a randomized study in 100 patients
with radiotherapy (entire pelvis: 4500 cGy, conedown: 720 cGy)
with or without WR-2721 (340 mg m22) in patients with advanced
rectal cancer. The radiation toxicity was scored on the Radiation
Therapy Oncology Group (RTOG) scale. A reaction was consid-
ered acute if it occurred within 105 days after the first radiotherapy
day. No moderate or severe late toxicity from radiation was seen in
the normal tissues in patients who received WR-2721. Five patients
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Table 3 Ongoing clinical trials using WR-2721 (PDQ clinical trial search)
Study design Tumour type Antineoplastic regimen No. of
studies
Phase I/II Myelodysplastic syndrome WR-2721 6
Phase II Breast, NSCLC Paclitaxel 3
Phase I/II NSCLC, ovar., Paclitaxel and CDDP or CBDCA 7
endometria adenocarcinomal
Phase I/II Colorect. Irinotecan 1
Phase III Dif. CDDP 1
Phase I/II Dif. CDDP and Gemcitabine 2
Phase I Acute myeloid leukaemia Cytarabine and Mitoxantrone 1
Phase I Dif Ifosfamide and CBDCA and Etoposide 1
Phase II Breast Mitoxantrone and Thiotepa and CYC 1
Head and Neck 5-FU and CDDP 1
Phase I/II Fludarabine 1
CBDCA 5 carboplatin, CDDP 5 cisplatin, CYC 5 cyclophosphamide NSCLC 5 non-small-cell lung cancer, Ovar. 5 ovarian, Dif. 5 different tumours,
Rect. 5 Rectal.treated with radiotherapy alone had a moderate or severe toxicity to
one or more of the following organs: skin, genitourinary or lower
gastrointestinal tract. The WR-2721 was administered i.v. before
each radiotherapy session. Although there was a significant reduc-
tion in late radiation-induced toxicity, there was no effect on acute
toxicity in this group of rectal cancer patients. There was no
evidence of tumour protection by WR-2721: 16% of the patients
randomized to the WR-2721 group had a complete response
compared with 10% in the group with radiotherapy only. This
difference is, however, not significant because of the small
numbers in each group; this is due to the fact that only 60% of the
patients were evaluable. In a phase II study (Buntzel et al, 1998) in
patients with head and neck cancer treated with radiotherapy and
carboplatin, WR-2721 was administered i.v. in 25 patients
compared with 14 patients in the control group. A reduced platelet
toxicity and mucositis was found in the WR-2721-treated group.
Brizel et al (1998) showed a reduction in the acute radiation-
induced toxicity (xerostomia) in patients with head and neck cancer
in the WR-2721-treated group compared with the control group.
To balance the overall effect of WR-2721, one has to take in
toaccount, on one hand, the reduction in radiotherapy-induced
toxicity and a small reduction of haematological and renal toxicity,
and on the other hand, the side-effects of the WR-2721 infusion.
However, with an improved premedication regimen, WR-2721 is
tolerable.
CLINICAL RESULTS OF CHEMOTHERAPY
PROTECTION BY GSH
In Table 2 different comparative clinical trials using GSH as a
chemoprotective agent are presented. For GSH, a protection of
cisplatin-induced toxicity is noted in ovarian cancer comparable
with that produced by WR-2721 (Smyth et al, 1997). In this
randomized, double-blind study, 151 patients with ovarian cancer
were treated with 100 mg m22 with or without GSH (3 g m22),
every 3 weeks for 6 cycles. Nephrotoxicity occurred in 39% who
received GSH versus 49% controls, and caused failure to complete
protocol in 11/74 versus 26/77. In addition, quality of life was
assessed, which showed a significant reduction in depression in
the GSH-treated group. No tumour protection was found.
A small, randomized study with cisplatin with and without GSH
has been published by Boglium et al (1996). In this study, 54
patients with ovarian cancer were treated with 50 or 75 mg m22
CDDP every 3 weeks for 9 or 6 courses respectively, with or
without 2.5 g m22 GSH. In a small group with a cumulative dose
of 500–675 mg m22 (ten patients without GSH and 13 patients
with GSH), there was a trend toward less severe neurotoxicity. No
difference in non-neurological side-effects were found. It can be
concluded that, taken in account with the results of the phase II
studies, GSH shows protective activity against cisplatin-induced
renal toxicity.
In Table 3, ongoing clinical trials with WR-2721 are listed
(PDQ clinical trial search), no trials are found with GSH in the
PDQ clinical trial search. For the future it would be interesting to
study the effect on the quality of life of both drugs (WR-2721 and
GSH) after chemotherapeutic and radiation regimens. An increase
in quality of life is expected when it is possible to prevent
mucositis, neurotoxicity, ototoxicity, cardiac failure and the
development of secondary tumours. For evaluation of protection,
objective tests are necessary.
DIFFERENCES BETWEEN THE
CHEMOPROTECTIVE EFFECTS OF WR-2721 AND
GSH
The basic structure of both sulfhydryl-containing drugs is
completely different. The polyamine-like structure of WR-2721
suggests it may have a greater protective effect on DNA. Different
organs are protected by WR-2721 and GSH. Based on the distrib-
ution studies of radioactive WR-2721 and GSH (Washburn et al,
1976; Ercan et al, 1994), radio- and chemotherapy protection for
kidney, heart, lung, mucosa, liver and bone marrow is expected for
WR-2721, and for GSH, protection is expected for kidney, liver
and urinary bladder. Based on the level of the enzyme, g-glutamyl
transpeptidase necessary for the membrane transport of GSH, and
according to animal data, GSH is likely to have a protective effect
on peripheral neurons (Romero et al, 1990; Hamers et al, 1993).
Based on the available laboratory data, WR-2721 shows protec-
tion against radiotherapy, cisplatin, alkylating agents, 5-FU and
taxanes, and GSH shows protection against alkylating agents and
cisplatin.
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Figure 3 The intracellular ‘uptake’ of GSHClinical data on all except radiation, alkylation and cisplatin/
CBDCA are weak. Clinical data from WR-2721 and GSH show
protection against renal and bone marrow toxicity. Importantly,
GSH can supply this protection without major side-effects.
However, on the above mentioned preclinical data, WR-2721 has,
theoretically, an extended clinical application.
FUTURE PROSPECTS
Local effects on mucous- and visceral membranes
Oral mucositis and rectal wall injury are important chemo- and
radiation treatment-related toxicities. Local application of WR-
2721 to the small bowel mucosa of rats before radiation provides
protection and this benefit is amplified when WR-2721 is in an
alkaline medium (Delaney et al, 1994). Local application of WR-
2721 rectally in 21 patients prior to each fraction of pelvic radia-
tion did not show a protective effect when compared to historical
controls treated without WR-2721. This was in spite of a high
concentration of alkaline phosphatase in the rectal wall (Ben-Josef
et al, 1995). The reasons for failure of this drug to protect the
rectosigmoid mucosa may be related to the method of administra-
tion: the rectum was not empty, only 30 ml were given and radia-
tion was given until 45 min later (Montana et al, 1992). In a phase
II study in patients with head and neck cancer having local radio-
therapy, less mucositis was found in the group that received WR-
2721 i.v. (Buntzel et al, 1998). Prevention of oral mucositis with
local application of WR-2721 has not been investigated to date.
The taste of WR-2721 (20 mg ml21) is acceptable (personal obser-
vation), but it is uncertain if the activity of alkaline phosphatase in
the mouth or saliva is sufficient to produce WR-2721 to the active
WR-1065 component. Alkaline phosphatase is present in the oral
mucosa, but the concentration is ten times lower than that of the
rectal mucosa. However, the concentration of alkaline phosphatase
is probably not the only factor necessary to convert WR-2721
because, based on in vitro experiments, myocytes have a low
degree of alkaline phosphatase but can convert WR-2127 to the
active compound (Dorr, 1996). Local application of GSH is also
interesting to investigate, although the effect is questionable
because the g-glutamyl-transferase concentration in the oral
mucosa and saliva is low (Sajjan et al, 1991; Schwint et al, 1992).
Recently, Alberts et al (1996) showed, in ovarian cancer, that
intraperitoneal (i.p.) cisplatin significantly improves survival and
has overall a significantly lower toxicity compared to i.v. cisplatin,
but in the i.p. group an increase of abdominal pain and dyspnoea
was found. Given WR-2721 i.v., only 1% of the dose appears in
the ascites (Van der Vijgh and Kerst, 1996), therefore WR-2721
might be considered for i.p. administration to circumvent intra-
abdominal distress. Based on monkey experiments of i.p. WR-
2721, where 100% of the radioactive WR-2721 was found
systemically with only a delay of approximately 10 min compared
with i.v. administration (Mangold et al, 1989), it is likely that side-
effects of i.p. WR-2721 would be similar to i.v. administration.
Neurotoxicity and ototoxicity
Neurotoxicity and ototoxicity are important irreversible problems
in some curatively treated patients, notably those with germ cell
tumours. Neuropathy has been reported to occur in 30–100% of
patients with germ cell tumours treated with cisplatin and is irre-
versible in 30–50% of the patients (Alberts and Noel, 1995; De Wit,
1995). A trial of WR-2721 in this group of patients has not been
undertaken, perhaps because of concern over tumour protection in
this curable disease and the knowledge that testicular germ cell
tumours can express alkaline phosphatases. However, in an animal
model with an alkaline phosphatase-positive tumour, no evidence is
found for tumour protection by WR-2721 (Dunn et al, 1996). In
Wistar rats, cisplatin-induced neuropathy was reduced after a dose
of 200 mg GSH per kg body weight (Hamers et al, 1993). In
hamsters, WR-2721 did not show any chemoprotection in combina-
tion with cisplatin on the cochlea (Kaltenbach et al, 1997).
However, in a phase I study with high-dose cisplatin, radiotherapy
and WR-2721 compared with a control group, there is an indication
of a decrease in ototoxicity (Rubin et al, 1995). Recently (McGuire
et al, 1996), the combination of cisplatin and paclitaxel has been
shown to be very active in ovarian cancer, with an increase in
median survival of 1.5 years, compared to the standard regimen of
cyclophosphamide and cisplatin. Since both cisplatin and paclitaxel
are known to be neurotoxic, the use of effective chemoprotective
agents may increase the quality of life in patients treated with this
regimen. Investigation of thiol compounds with this combination
would therefore be of interest. Sensitive objective tests of neuro-
logic function will be important to accurately document the impact
of cytoprotective agents in this setting.
Cardiac failure
Cardiac failure after chemo- and radiotherapy may arise as a late
complication 5–10 years after treatment, often occurring in the
subset of relatively young patients successfully ‘cured of the
cancer’ (Lipschulz et al, 1991; Steinherz and Yahalon, 1993;
Gyenes et al, 1996; Shapiro and Henderson, 1994). Dexrazoxane
(ICRF-187, Zinecard, ADR-529), another chemoprotective agent,
has been shown to significantly decrease anthracycline-related
cardiotoxicity (Swain et al, 1997), without a decrease in survival.
However, the patients treated had metastatic breast cancer with a
median survival of only 5 months. There are only a few publica-
tions of the effect of thiols in this setting (Dorr, 1996). In vitro
experiments with cardiac myocytes showed a decrease in the
doxorubicin-related toxicity after incubation with WR-2721. An
interesting observation in the WR-2721-treated cells was the
detection of an increase in the GSH content (Dorr, 1996). No clin-
ical studies with WR-2721 and GSH as protectors of radio- and
chemotherapy-induced cardiac toxicity have been carried out.
Cardiac failure after chemotherapy is often a late symptom.
Therefore, objective early tests to demonstrate cardiac dysfunction
have to be developed to evaluate the effect of protective agents at
an early stage. In order to develop objective tests to evaluate
cardiotoxicity, an awareness of different types of cardiotoxicity
caused by chemo- and radiotherapy is required. Cardiotoxicity can
be divided into three types of toxicity: (1) due to myocardial
damage, (2) due to vascular damage, (3) due to activation- and
conduction system damage (neurotoxicity). For the myocardial
damage, a MUGA scan is a reasonable objective test. For the other
two types of toxicities, objective early tests have to be developed.
Therapy-induced secondary cancer
The use of radio- and chemotherapy has placed a large number of
patients at potential risk for developing a treatment-related malig-
nancy. On the other hand, it is becoming more apparent that host
factors, for example a germline mutation in p53, can also increase
the risk of developing a second tumour.
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chemotherapy-induced mutation in hamster cells (Hill et al, 1986;
Nagy and Grdina, 1986; Nagy et al, 1986), and reduced the proto-
oncogene c-myc expression (Liu et al, 1997) and delayed a cell cycle
progression and build-up cells in the G2 phase of the cell cycle
(Murley et al, 1997). Pretreatment with amifostine reduced mutation
frequency in cells from mice given radiation, cisplatin or cyclophos-
phamide (Kataoka et al, 1992; Grdina et al, 1992). WR-2721 has the
ability to protect against radiation carcinogenesis. In mice treated
with WR-2721, 26% of radiation-induced sarcomas developed
compared with 87% in the mice exposed to radiation only (Milas et
al, 1984). In the clinical setting, an advantage of WR-2721 and GSH
may therefore be their potential to reduce the development of radio-
and chemotherapy-induced secondary tumours.
CONCLUSION
WR-2721 can provide selective protection against platinum and
alkylating agents related to renal- and bone marrow toxicity and
radiation-induced toxicity. Based on the randomized study of
Smyth et al (1997) and phase II studies, GSH has the same protec-
tive profile as WR-2721 when given prior to cisplatin. GSH has no
significant side-effects and is therefore a potential alternative for
WR-2721. An important remark concerning these radio- and
chemotherapy protective agents is that, when given extracellularly,
no tumour resistance to radio- and chemotherapy has been noticed.
Although these drugs show protection against chemotherapy-
related renal- and bone marrow toxicity, and WR-2721 shows a
protection against the toxicity of radiotherapy, the magnitude of
this protection has no impact on the standard chemotherapeutic
regimens. New studies should focus on the magnitude of clinical
cytoprotection and the real clinical benefit. These agents may be
useful in increasing the quality of life by decreasing mucositis,
neurotoxicity, ototoxicity and cardiac toxicity, but this is specula-
tive and studies to confirm this are needed. For preventing
mucositis without the side-effect of systemically administered
WR-2721, local application would be interesting to study.
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